Any current/future new fundraising through debt or equity?

The company currently remains net cash on standalone basis with over INR 300 crores net cash as of now. For the subsidiary, there may be a requirement of INR 100-150 crores debt for first-phase expansions by FY '27. Overall, consolidated net debt might rise marginally by INR 50-100 crores by FY '27 due to ongoing capex. Capital expenditures are planned over next 2 years: INR 150-200 crores in standalone and INR 700+ crores in subsidiary (split in two phases). No specific mention of new fundraising via equity or large debt issuance; company appears to be funding expansions through internal accr

Any current/future capex/capital investment/strategic investment?

Greenfield project by subsidiary Balaji Specialty Chemicals Limited worth approx. INR 750 crores, to manufacture specialty chemicals like Hydrogen Cyanide, Sodium Cyanide, EDTA derivatives, targeting commissioning by end FY '25-'26. Brownfield expansion for EDA-based products at Unit I, expected commissioning in FY '26-'27. Standalone capital expenditure of INR 150-200 crores planned, including modification and debottlenecking of existing plants. Acetonitrile plant capacity expansion and technology upgrade targeted for commissioning in FY '26-'27. New plants planned for NBPT (2,500 tons/annum)

Future growth expectations in sales/revenue/volumes?

Expecting a minimum volume growth of 10% to 12% in the current financial year (FY '26). Positive demand environment noted in April-May FY '26 across products with improved pricing, though recent raw material price pressures due to geopolitical tensions exist. Full utilization of new plants like Dimethyl Ether (DME), N-Methyl Morpholine (NMM), and Isopropyl amine expected by end of FY '26 or early FY '27, supporting revenue growth. Brownfield expansion at subsidiary (BSC Unit I) and new product launches targeted for FY '26-27 to drive top-line growth. Standalone revenue dipped slightly

Future growth expectations in earnings/operating earnings/profits/EPS?

Expecting volume growth of 10% to 12% in the current financial year (Page 7). Expansion projects like Dimethyl Ether (DME), MIPA/DIPA, NMM, NBPT expected to be commercialized by FY '27 end (Page 5). Brownfield expansion for EDA-based products and greenfield projects expected to improve capacity and margins by FY '27 (Pages 4, 7). Anticipated improvement in EBITDA and PAT margins aligned with industry recovery starting Q4 FY '25 (Page 4). Expansion in subsidiary (Balaji Specialty Chemicals) with INR 750 crores project expected to positively impact revenues by FY '27 (Pages 4, 9). EBITDA margin

Balaji AminesQ4 FY25Chemicals & Petrochemicals

Balaji Amines Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,848.8P/E: 29.3Market Cap: ₹6.0K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Expecting a minimum volume growth of 10% to 12% in the current financial year (FY '26).
Positive demand environment noted in April-May FY '26 across products with improved pricing, though recent raw material price pressures due to geopolitical tensions exist.
Full utilization of new plants like Dimethyl Ether (DME), N-Methyl Morpholine (NMM), and Isopropyl amine expected by end of FY '26 or early FY '27, supporting revenue growth.
Brownfield expansion at subsidiary (BSC Unit I) and new product launches targeted for FY '26-27 to drive top-line growth.
Standalone revenue dipped slightly in FY '25 but capacity expansions and product diversification are laying foundation for recovery and growth.
Additional revenue generation from DME plant estimated around INR 70 per kg, with 50,000 tons targeted in FY '26 and 70,000 tons in FY '27.
Overall, growth expected from both volume and capacity expansions with improved utilization and new product commercialization.

Margin guidance

Category 3

Expecting volume growth of 10% to 12% in the current financial year (Page 7).
Expansion projects like Dimethyl Ether (DME), MIPA/DIPA, NMM, NBPT expected to be commercialized by FY '27 end (Page 5).
Brownfield expansion for EDA-based products and greenfield projects expected to improve capacity and margins by FY '27 (Pages 4, 7).
Anticipated improvement in EBITDA and PAT margins aligned with industry recovery starting Q4 FY '25 (Page 4).
Expansion in subsidiary (Balaji Specialty Chemicals) with INR 750 crores project expected to positively impact revenues by FY '27 (Pages 4, 9).
EBITDA margin guidance around 19%-20%, with stabilization expected from new product capacities (Page 12).
Net debt expected to remain low, supporting financial stability and growth (Page 10).
Overall growth driven by capacity expansion, new product commercialization, and anticipated market recovery.

See what Balaji Amines management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company currently remains net cash on standalone basis with over INR 300 crores net cash as of now.
For the subsidiary, there may be a requirement of INR 100-150 crores debt for first-phase expansions by FY '27.
Overall, consolidated net debt might rise marginally by INR 50-100 crores by FY '27 due to ongoing capex.
Capital expenditures are planned over next 2 years: INR 150-200 crores in standalone and INR 700+ crores in subsidiary (split in two phases).
No specific mention of new fundraising via equity or large debt issuance; company appears to be funding expansions through internal accruals and moderate borrowing.
The focus is on careful incremental debt taking aligned with expansion capex while balancing net cash position.
No clear mention of immediate or large-scale fundraising in the transcript.

Order book

The transcript provided does not specifically mention details about the current or expected order book or pending orders for Balaji Amines Limited. However, relevant insights related to business outlook and capacity utilization include: - Positive demand observed across products in April and May, with expectations of volume growth of 10-12% this year. - New product commercializations (DME, MIPA/DIPA, NMM NBPT) planned largely by FY '27 end. - Capacity utilization expected to improve as plants for new products commission gradually. - Antidumping duty filings are under consideration to protect certain product segments (e.g., DMF). - The company anticipates increased capacity utilization in subsidiary and standalone plants post brownfield and greenfield expansions, supporting future order fulfillment capabilities. - No explicit figures or timelines for order book or pending orders disclosed. Thus, detailed current or pending order book data is not directly provided in the transcript.

See what Balaji Amines management said on order book — free account, 30 seconds.

Capex plans

Yes

Greenfield project by subsidiary Balaji Specialty Chemicals Limited worth approx. INR 750 crores, to manufacture specialty chemicals like Hydrogen Cyanide, Sodium Cyanide, EDTA derivatives, targeting commissioning by end FY '25-'26.
Brownfield expansion for EDA-based products at Unit I, expected commissioning in FY '26-'27.
Standalone capital expenditure of INR 150-200 crores planned, including modification and debottlenecking of existing plants.
Acetonitrile plant capacity expansion and technology upgrade targeted for commissioning in FY '26-'27.
New plants planned for NBPT (2,500 tons/annum) expected to commence in next financial year.
Dimethyl Ether (DME) plant commissioned in FY '25-'26 with capacity utilization ramp-up planned.
Isopropyl amines plant reconfiguration at Unit I (20-21 tons/day) awaiting pollution clearance.
All projects funded through internal accruals, reflecting strong financials.

Track Balaji Amines — get its next earnings analysis in your feed

How does Balaji Amines rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisBalaji Amines

Rev 3Mar 3

See where Balaji Amines sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Balaji Amines rank in Chemicals & Petrochemicals?

Compare Balaji Amines against every Chemicals & Petrochemicals company (Q4 FY25) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Balaji Amines's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Alufluoride Ltd (Q1 FY27)
Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr
POCL Enterprises Ltd (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
Deepak Nitrite Ltd (Q2 FY27)
Q2 FY27 total revenue: ₹3,091 crore, up 61% YoY (Page 1, 4, 5, 6, 10, 11) . Key investor presentation takeaways from Deepak Nitrite Ltd's Q2 FY27 investor prese
Privi Speciality Chemicals Ltd (Q2 FY27)
19,239.47 lakhs (approximately 33.9% growth). Key results statement takeaways from Privi Speciality Chemicals Ltd's Q2 FY27 results statement — and how it ranks

Compare:vs Solar Industries vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Balaji Amines Q4 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Balaji Amines rank in Chemicals & Petrochemicals?

Continue your research

What Balaji Amines's management said in earlier quarters

Others in Chemicals & Petrochemicals this season